Last updated on August 2019

Study for patients with stable heart failure of ischemic origin


Brief description of study

We are carrying out a clinical trial with an investigational drug that is being developed with the intention of treating patients with heart failure of ischemic origin (heart failure characterised by a reduced blood supply to the heart).

The main purpose of the study will be to assess how safe the study drug is and to determine how long the study drug will remain in the body. We may also study how the study drug will affect the body.

The information gathered during this clinical trial may be used to support further drug development, including larger trials in patients with heart failure.

 

In recognition of the time and effort involved in taking part in this study, you will receive £1,692 (£1,027 study payment, £505 bonus and up to £160 for travel expenses) on completion of the study provided you comply fully with all the study requirements.

 

For more information about this study:

  • You may also contact us directly; Azar Alexander-Sefre can be reached via e-mail at a.sefre@richmondpharmacology.com or via phone at +44 (0) 207 042 5800

 

Clinical Study Identifier: TX227267

Find a site near you

Start Over

Richmond Pharmacology

1a Newcomen Street, London Bridge, London, London United Kingdom
  Connect »